Aardvark Financial Statements From 2010 to 2026

AARD Stock   14.84  0.57  3.99%   
Aardvark Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aardvark Therapeutics' valuation are provided below:
Market Capitalization
310.7 M
Earnings Share
(2.53)
There are over one hundred one available fundamental signals for Aardvark Therapeutics Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Aardvark Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Enterprise Value is expected to grow to about 155.1 M
Check Aardvark Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aardvark Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.5 M, Interest Income of 1.5 M or Depreciation And Amortization of 13.7 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Aardvark financial statements analysis is a perfect complement when working with Aardvark Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Aardvark Stock
Check out the analysis of Aardvark Therapeutics Correlation against competitors.

Aardvark Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets93.6 M89.1 M28.7 M
Slightly volatile
Short and Long Term Debt Total940.6 K895.9 K363.7 K
Slightly volatile
Other Current Liabilities2.8 M2.6 M646.8 K
Slightly volatile
Total Current Liabilities5.9 M5.7 M1.5 M
Slightly volatile
Property Plant And Equipment Net887.5 K845.2 K347 K
Slightly volatile
Accounts Payable2.8 M2.6 M712.8 K
Slightly volatile
Cash74.4 M70.9 M24.6 M
Slightly volatile
Non Current Assets Total4.1 M3.9 M878.9 K
Slightly volatile
Non Currrent Assets Other3.2 MM531.9 K
Slightly volatile
Cash And Short Term Investments88.9 M84.7 M27.5 M
Slightly volatile
Common Stock Shares Outstanding13 M14.8 M10.6 M
Slightly volatile
Short Term Investments14.5 M13.8 M2.8 M
Slightly volatile
Liabilities And Stockholders Equity93.6 M89.1 M28.7 M
Slightly volatile
Non Current Liabilities Total78.9 M146.3 M57 M
Slightly volatile
Capital Lease Obligations940.6 K895.9 K363.7 K
Slightly volatile
Other Current Assets454.3 K545.1 K404.1 K
Slightly volatile
Other Stockholder Equity3.4 M4.2 M2.8 M
Slightly volatile
Total Liabilities81.5 M152 M58.3 M
Slightly volatile
Property Plant And Equipment Gross887.5 K845.2 K347 K
Slightly volatile
Total Current Assets89.5 M85.3 M27.9 M
Slightly volatile
Non Current Liabilities Other17.2 K29.9 K18.9 K
Very volatile
Net Working Capital83.6 M79.6 M26.4 M
Slightly volatile
Short Term Debt201.7 K388.7 K137.7 K
Slightly volatile

Aardvark Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income1.5 M2.8 M566.1 K
Slightly volatile
Interest Income1.5 M2.8 M566.1 K
Slightly volatile
Depreciation And Amortization13.7 K14.4 K92.4 K
Slightly volatile
Selling General Administrative3.7 M6.1 M3.1 M
Slightly volatile
Other Operating Expenses15.2 M26.2 M12.9 M
Slightly volatile
Research Development10.6 M20 M8.6 M
Slightly volatile
Cost Of Revenue13.7 K14.4 K92.4 K
Slightly volatile
Total Operating Expenses15.2 M26.2 M12.9 M
Slightly volatile
Reconciled Depreciation13.7 K14.4 K92.4 K
Slightly volatile

Aardvark Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation426.8 K504.9 K414.1 K
Pretty Stable
Begin Period Cash Flow13.9 M8.8 M23.4 M
Slightly volatile
Other Cashflows From Financing Activities98.6 M93.9 M21.7 M
Slightly volatile
Depreciation13.7 K14.4 K92.4 K
Slightly volatile
Other Non Cash Items404.4 K425.7 K3.1 M
Slightly volatile
End Period Cash Flow74.4 M70.9 M24.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation5.456.136.6922
Slightly volatile
Cash Per Share5.395.142.266
Slightly volatile
Income Quality0.660.790.7789
Very volatile
ROE0.40.430.4546
Slightly volatile
Net Debt To EBITDA1.522.421.6725
Slightly volatile
Current Ratio18.4417.324.6233
Slightly volatile
Capex Per Share0.00680.00760.0083
Slightly volatile
Interest Debt Per Share0.0570.05430.0314
Slightly volatile
Debt To Assets0.01510.01160.015
Slightly volatile
Ebt Per Ebit1.121.041.1502
Slightly volatile
Quick Ratio18.4417.324.6233
Slightly volatile
Cash Ratio16.7514.3922.9788
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9888
Slightly volatile
Debt Ratio0.01510.01160.015
Slightly volatile
Return On Equity0.40.430.4546
Slightly volatile

Aardvark Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap135.7 M166.3 M146 M
Slightly volatile
Enterprise Value155.1 M142.5 M129.9 M
Slightly volatile

Aardvark Fundamental Market Drivers

About Aardvark Therapeutics Financial Statements

Aardvark Therapeutics stakeholders use historical fundamental indicators, such as Aardvark Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Aardvark Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aardvark Therapeutics' assets and liabilities are reflected in the revenues and expenses on Aardvark Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aardvark Therapeutics Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue14.4 K13.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aardvark Therapeutics is a strong investment it is important to analyze Aardvark Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aardvark Therapeutics' future performance. For an informed investment choice regarding Aardvark Stock, refer to the following important reports:
Check out the analysis of Aardvark Therapeutics Correlation against competitors.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aardvark Therapeutics. If investors know Aardvark will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aardvark Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.53)
Return On Assets
(0.31)
Return On Equity
(0.48)
The market value of Aardvark Therapeutics is measured differently than its book value, which is the value of Aardvark that is recorded on the company's balance sheet. Investors also form their own opinion of Aardvark Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aardvark Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aardvark Therapeutics' market value can be influenced by many factors that don't directly affect Aardvark Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aardvark Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aardvark Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aardvark Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.